Berger William E, Rosenwasser Lanny, Atwater J Spencer
Southern California Research, Mission Viejo, CA, USA.
Manag Care Q. 2003 Spring;11(2):8-11.
Some managed care companies are considering reducing or eliminating coverage for several second-generation antihistamines prescribed to treat patients with allergic rhinitis, chronic idiopathic hives, and other allergy-related conditions. Treatment options for all patients with allergic and immunologic diseases should reflect accepted standards of medical care. Prescription policies limiting coverage and/or use of second-generation antihistamines are medically inappropriate, below current national standards of practice in the field of allergic and immunologic diseases, and may increase health expenditures in the long-term. Any action to reduce or limit coverage will not only diminish the quality of medical care for allergy patients but have significant health and safety implications for the general public.
一些管理式医疗公司正在考虑减少或取消对几种第二代抗组胺药的承保范围，这些药物用于治疗过敏性鼻炎、慢性特发性荨麻疹和其他过敏相关病症的患者。所有过敏性和免疫性疾病患者的治疗选择都应符合公认的医疗护理标准。限制第二代抗组胺药承保范围和/或使用的处方政策在医学上是不合适的，低于目前过敏性和免疫性疾病领域的国家标准做法，并且从长期来看可能会增加医疗支出。任何减少或限制承保范围的行动不仅会降低过敏患者的医疗质量，还会对公众的健康和安全产生重大影响。
